Twist Bioscience Now Shipping Synthetic RNA Positive Controls for Omicron (B.1.1.529/BA.1) SARS-CoV-2 Variant for Development of Accurate Diagnostic Tests

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that synthetic RNA positive controls are now available for the SARS-CoV-2 Omicron (B.1.1.529/BA.1) variants first identified in South Africa. Since the initial...

Click to view original post